Issue: January 2015
October 18, 2014
2 min read
Save

Response to AREDS formulation depends on genotype

Issue: January 2015
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO – The response to AREDS supplementation in patients with age-related macular degeneration varies greatly based on CFH and ARMS2 risk, according to a speaker here.

Perspective from Pravin U. Dugel, MD

In a statistical genetic analysis published in Ophthalmology, Carl C. Awh, MD, and colleagues delineated risk of AMD progression in genotype subgroups culled from the AREDS cohort.

Carl C. Awh

“We predicted an adverse response to AREDS formulation or zinc in patients with two CFH and zero ARMS2 risk alleles,” Awh said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.

Awh and fellow authors elucidated AMD progression risk in four distinct genotype groups with higher or lower ARMS2 and CFH risk. Patients with high ARMS2 and low CFH risk responded well to the AREDS formulation or zinc.

“However, those with high CFH and no ARMS2 risk had an opposite response to the AREDS formulation or zinc and had much higher progression,” Awh said.

Using the AREDS Study Group genotyping, it’s easy to identify patients in genotypes group one, two, three and four,” he said. “So, we know which patients fall into which genotype group. We know how many patients are in each group and we know how many patients progressed to advanced AMD at 7 years.”

Disclosure: Awh has financial relationships with Arctic Dx, Bausch + Lomb, Genentech, GlaxoSmithKline, Katalyst, Notal Vision, Regeneron, Synergetics Inc.  and Volk Optical.